Some people find it takes more planning, while others find it straightforward
"For the time period between November 1, 2023, and October 31, 2024, which is the time period used to determine which drugs were eligible for negotiation for this second cycle, about 5.3 million people with Medicare Part D coverage used these drugs to treat a variety of conditions, such as cancer, type 2 diabetes, and asthma," the CMS fact sheet states
Novo Nordisk has also asked European Union regulators to expand the use of the drug for heart problems
GLP-1 is involved in the regulation of glucose metabolism, including the enhancement of insulin secretion in response to meals, inhibition of glucagon release, and slowing of gastric emptying